Filtered By:
Condition: Diabetes Type 2
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 326 results found since Jan 2013.
Transient left bundle branch block associated with very high coronary artery calcium: a case report
We present a case of very high CAC in a 64-year-old woman with hypertension, type 2 diabetes, and hyperlipidemia presenting with dyspnea. Initial electrocardiogram (ECG) demonstrated normal conduction with a heart rate of 76 beats/min, but new T-wave inversions in V1-V4 and a high-sensitivity troponin-I (hsTnI) value of 6 ng/L (normal < 6 ng/L). Repeat ECG in the emergency department showed normal sinus rhythm (heart rate of 80 beats/min); however, it subsequently demonstrated a left bundle branch block (LBBB) with a repeat hsTnI of 7 ng/L. Stress testing with pharmacologic single-photon emission computerized tomography...
Source: Atherosclerosis - September 19, 2023 Category: Cardiology Authors: Alexander C Razavi Sindhu Prabakaran Mariem Sawan Lakshmi Tummala Ifeoma Onuorah Sagar B Amin Marly van Assen Carlo N De Cecco Arshed A Quyyumi Seamus P Whelton Laurence S Sperling Francois G Rollin Source Type: research
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry
CONCLUSION: Approximately 2 years after publication of the guidelines, LDL-C and non-HDL-C goal attainment was rarely achieved in patients with T1D and T2D with a high or very high cardiovascular risk.PMID:37694759 | DOI:10.1111/dom.15264
Source: Atherosclerosis - September 11, 2023 Category: Cardiology Authors: Julia Brandts Sascha R Tittel Peter Bramlage Thomas Danne Johanna M Brix Stefan Zimny Christoph H J Heyer Reinhard W Holl Dirk M üller-Wieland Source Type: research
Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment
CONCLUSION: AT combined with EZ can effectively improve glucose, lipids, inflammation and upregulate serum bilirubin in patients with HY combined with T2DM.PMID:37632947
Source: Alternative Therapies in Health and Medicine - August 26, 2023 Category: Complementary Medicine Authors: Siyu Zhu Tehasi Wang Qingyi Wang Mengyu Du Source Type: research
Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
CONCLUSIONS AND RELEVANCE: A protein risk score was significantly associated with ASCVD events in primary and secondary event populations. When added to clinical risk factors, the protein risk score and polygenic risk score both provided statistically significant but modest improvement in discrimination.PMID:37606673 | DOI:10.1001/jama.2023.13258
Source: Atherosclerosis - August 22, 2023 Category: Cardiology Authors: Hannes Helgason Thjodbjorg Eiriksdottir Magnus O Ulfarsson Abhishek Choudhary Sigrun H Lund Erna V Ivarsdottir Grimur Hjorleifsson Eldjarn Gudmundur Einarsson Egil Ferkingstad Kristjan H S Moore Narimon Honarpour Thomas Liu Huei Wang Thomas Hucko Marc S S Source Type: research
Atorvastatin lowers < sup > 68 < /sup > Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes
CONCLUSIONS/INTERPRETATION: 68Ga-DOTATATE uptake across the cardio-haematopoietic axis was lower after statin therapy in individuals with type 2 diabetes. Therefore, 68Ga-DOTATATE is promising as a metric for vascular and haematopoietic inflammation in intervention studies using anti-inflammatory therapeutics in individuals with type 2 diabetes.TRIAL REGISTRATION: ClinicalTrials.gov NCT05730634.PMID:37581619 | DOI:10.1007/s00125-023-05990-9
Source: Atherosclerosis - August 15, 2023 Category: Cardiology Authors: Reindert F Oostveen Yannick Kaiser Mia R St åhle Nick S Nurmohamed Evangelos Tzolos Marc R Dweck Jeffrey Kroon Andrew J Murphy Damini Dey Piotr J Slomka Hein J Verberne Erik S G Stroes Nordin M J Hanssen Source Type: research
HDL abnormalities in type 2 diabetes: Clinical implications
Atherosclerosis. 2023 Aug 3:117213. doi: 10.1016/j.atherosclerosis.2023.117213. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) represents the primary cause of mortality among patients with Type 2 Diabetes Mellitus (T2DM). In this population, High-Density Lipoprotein (HDL) particles exhibit abnormalities in number, composition, and function, culminating in diminished anti-atherosclerotic capabilities despite normal HDL cholesterol (HDL-C) concentrations. Hyperglycemic conditions contribute to these alterations in HDL kinetics, composition, and function, causing T2DM patients' HDL particles to e...
Source: Atherosclerosis - August 14, 2023 Category: Cardiology Authors: Alexandro J Martagon Rafael Zubir án Rogelio Gonz ález-Arellanes Samantha Praget-Bracamontes J Adri án Rivera-Alcántara Carlos A Aguilar-Salinas Source Type: research
Visfatin and Subclinical Atherosclerosis in Type 2 Diabetes: Impact of Cardiovascular Drugs
Conclusions: Visfatin could be used as a marker of subclinical atherosclerosis in patients with T2DM, especially in males. The assessment of visfatin concentration could aid in identifying individuals who could benefit from implementing preventive measures against atherosclerosis.PMID:37512134 | PMC:PMC10386106 | DOI:10.3390/medicina59071324
Source: Medicina (Kaunas) - July 29, 2023 Category: Universities & Medical Training Authors: Kati K ärberg Alastair Forbes Margus Lember Source Type: research
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
Curr Atheroscler Rep. 2023 Jul 29. doi: 10.1007/s11883-023-01135-w. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: The aim of this study is to investigate the protective effects of different statin classes, intensity, and cumulative dose-dependent against primary ischemic stroke in patients with T2DM.RECENT FINDINGS: The Cox hazards model was used to evaluate statin use on primary ischemic stroke. Case group: T2DM patients who received statins; control group: T2DM patients who received no statins during the follow-up. Adjusted hazard ratio (aHR) for primary ischemic stroke was 0.45 (95% CI: 0.44 to 0.46). Cox regression ...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Jung-Min Yu Wan-Ming Chen Ben-Chang Shia Szu-Yuan Wu Source Type: research
Visfatin and Subclinical Atherosclerosis in Type 2 Diabetes: Impact of Cardiovascular Drugs
Conclusions: Visfatin could be used as a marker of subclinical atherosclerosis in patients with T2DM, especially in males. The assessment of visfatin concentration could aid in identifying individuals who could benefit from implementing preventive measures against atherosclerosis.PMID:37512134 | DOI:10.3390/medicina59071324
Source: Medicina (Kaunas) - July 29, 2023 Category: Universities & Medical Training Authors: Kati K ärberg Alastair Forbes Margus Lember Source Type: research
